Fenfluramine treatment for Dravet syndrome: Long term real‐world analysis demonstrates safety and reduced health care burden
Epilepsia · 2025
DOI: 10.1111/epi.18241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Alessandra Boncristiano und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience and Medical Genetics, Children's Hospital Meyer IRCCS, Florence, Italy. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Fenfluramine, Anticonvulsants. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health, Italian Ministry of University and Research, Ministero della Salute.
Abstract (Originalsprache)
Objective
Fenfluramine (FFA), stiripentol (STP), and cannabidiol (CBD) are approved add‐on therapies for seizures in Dravet syndrome (DS). We report on the long‐term safety and health care resource utilization (HCRU) of patients with DS treated with FFA under an expanded access program (EAP).
Methods
A cohort of 124 patients received FFA for a median of 2.8 years (34.4 months). We compared data on safety and HCRU during FFA treatment with those from a same pre‐treatment period. Echocardiography was conducted every 6 months. Information collected included gender, age, and auxological parameters (height, weight, and body mass index [BMI]) at the start (T0) and follow‐up (T1); FFA treatment details (start, withdrawal, dosage); adverse events (AEs); and HCRU data including hospital admissions, status epilepticus (SE) episodes, and rescue medication use. We grouped patients by weight: ≤37.4 kg ( n = 68, 54.8%) and ≥37.5 kg ( n = 56; 45.1%), with FFA dosing adjusted accordingly. Statistical analyses included paired t test, Wilcoxon signed‐rank test, Kaplan–Meier analysis, and Bonferroni correction to adjust for multiple testing.
Results
Mean age was 47 months at clinical diagnosis and 81 months at T0. The last follow‐up average FFA dose was .5 mg/kg/day, with a median of .4 mg/kg/day. FFA led to a 9.5% reduction in prior treatment load. At last follow‐up, 118 of 124 (91.5%) remained on FFA. Rescue medication use decreased significantly from 4.5 to 1, hospitalizations from 1 to 0, and SE episodes from 0–240 to 0–180 ( p < .001 for all). Seizure freedom was achieved in 9 of 118 patients (7.6%). AEs occurred in 39 of 124 patients (31.5%), with no cardiac issues or deaths. There was an overall mean reduction in BMI, with no statistical significance, and never requiring FFA withdrawal. Significance FFA is well tolerated, without cardiac toxicity, and reduces treatment load and HCRU, suggesting improved patient management. BMI reduction in young children highlights the need for growth and nutritional monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience and Medical Genetics, Children's Hospital Meyer IRCCS, Florence, Italy.
- Neurofarba Department, University of Florence, Florence, Italy.
- Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital IRCCS, Full Member of European Reference Network EpiCARE, Rome, Italy.
- University Hospitals KU Leuven, Leuven, Belgium.
- Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy.
- Child Neuropsychiatry Unit, Department of Children and Maternal Health, AOUI Verona, Full Member of European Reference Network EpiCARE, Verona, Italy.
ORCID-Profile: Nicola Specchio, Francesca Darra, Michela Quintiliani, Carla Marini, Tiziana Granata, Pasquale Striano, Antonella Riva
Förderung
- Italian Ministry of Health
- Italian Ministry of University and Research
- Ministero della Salute
Zitieren
APA
Boncristiano, A., Balestrini, S., Doccini, V., Specchio, N., Pietrafusa, N., Trivisano, M., Darra, F., Cossu, A., Battaglia, D., Quintiliani, M., Gambardella, M. L., Parente, E., Monni, R., Matricardi, S., Marini, C., Ragona, F., Granata, T., Striano, P., Riva, A., & Guerrini, R. (2025). Fenfluramine treatment for Dravet syndrome: Long term real‐world analysis demonstrates safety and reduced health care burden. Epilepsia. https://doi.org/10.1111/epi.18241
Vancouver
Boncristiano A, Balestrini S, Doccini V, Specchio N, Pietrafusa N, Trivisano M, et al. Fenfluramine treatment for Dravet syndrome: Long term real‐world analysis demonstrates safety and reduced health care burden. Epilepsia. 2025. doi:10.1111/epi.18241
BibTeX
@article{Boncristiano2025,
author = {Boncristiano, Alessandra and Balestrini, Simona and Doccini, Viola and Specchio, Nicola and Pietrafusa, Nicola and Trivisano, Marina and Darra, Francesca and Cossu, Alberto and Battaglia, Domenica and Quintiliani, Michela and Gambardella, M Luigia and Parente, Eliana and Monni, Rita and Matricardi, Sara and Marini, Carla and Ragona, Francesca and Granata, Tiziana and Striano, Pasquale and Riva, Antonella and Guerrini, Renzo},
title = {Fenfluramine treatment for Dravet syndrome: Long term real‐world analysis demonstrates safety and reduced health care burden},
journal = {Epilepsia},
year = {2025},
doi = {10.1111/epi.18241}
}
EUVIMED